• Pipeline
  • Program Target
    SNCA x IGF1R
  • Disease Indication
    Parkinson’s Disease
  • Development Stage
    Clinical Development (Phase 1)
The propagation of aggregated forms of alpha-synuclein (α-synuclein, SNCA) appears to be critical for the etiology of Parkinson’s disease and multiple system atrophy. ABL301 selectively targets aggregated forms of α-synuclein as a potential disease target, avoiding those of its normal, monomeric form. Since poor delivery of antibodies past the blood-brain-barrier is thought to be one of the major obstacles for CNS-related drug development, ABL301 also has a shuttle antibody that allows for improved delivery of antibody therapeutics into the brain. This dual mechanism will enable antibody therapeutics to more efficiently reach their targets, leading to better therapeutic efficacy compared to conventional monoclonal antibodies.
Figure from biopharmadeal makers (2017)
좌우스크롤 Figure from biopharmadeal makers (2017)